Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

ipates that there will be one or more generic competitors to ADDERALL XR in the ADHD market beginning April 2009. ADDERALL XR is, in revenue terms, Shire's most significant product representing 36% of total revenues in 2008 (2007: 42%). The Group expects that sales of VYVANSE will partially offset any decline in sales of ADDERALL XR and that VYVANSE prescriptions will come from a number of sources, including patients who are new to ADHD treatment, patients who previously were taking ADDERALL XR, and patients who were taking another ADHD medication.

Shire is engaged in various legal proceedings with generic manufacturers with respect to its ADDERALL XR and CARBATROL patents, as well as the patents for certain other products.

R&D

Over the last five years Shire has focused its R&D efforts on products in its core therapeutic areas, which meet the needs of the specialist physician. The Group has also concentrated its resources on obtaining regulatory approval for later-stage pipeline products within its core therapeutic areas.

Evidence of the successful execution of this strategy can be seen from the progression of the Group's development pipeline over the last five years. Since January 2004, nine products have received regulatory approval; six in the US (FOSRENOL and EQUETRO in 2004, DAYTRANA and ELAPRASE in 2006, LIALDA and VYVANSE in 2007) and three in Europe (FOSRENOL in 2005, ELAPRASE and MEZAVANT in 2007). The Group has another one product in registration in the US (INTUNIV) and one in registration in the EU (DAYTRANA).

Shire's strategy is focused on the development of product candidates that have a lower risk profile. R&D costs in 2009 will include expenditure on several pre-clinical to Phase 3 studies and Phase 3(b) and Phase 4 studies to support recently launched products in the Specialty Pharmaceuticals and HGT businesses, and the development of new projects
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... SAN DIEGO , Sept. 16, 2014  Biocom, ... life science community, recognizes the 9 th ... to the value of IT technologies in improving our ... California is one of the world,s most ... from EHRs to mobile health applications to genomic testing ...
(Date:9/16/2014)... created a deicing film for radar domes have now ... for glass. , The new work by Rice ... surfaces from windshields to skyscrapers free of ice and ... , The technology was introduced this month in ... Interfaces . , The material is made of ...
(Date:9/16/2014)... Fresne, President and CEO of Egenix, Inc. is pleased to ... its Scientific Advisory Committee. Dr. Vagner, a graduate ... performed research at Embl (European Molecular Biology Laboratory) Heidelberg, ... of health and medical research. He is a Research Director ... France , and at the Gustave Roussy ...
(Date:9/16/2014)... Sept. 16, 2014   Synthetic Biologics, Inc. ... novel anti-infective biologic and drug programs targeting specific ... the completion of the Company,s Investor Day in ... its irritable bowel syndrome (IBS) program, including its ... In the keynote presentation, Mark ...
Breaking Biology Technology:Biocom Recognizes National Health IT Week 2Nanoribbon film keeps glass ice-free 2New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3
... conjunction with,CorVel Corporation,s (Nasdaq: CRVL ) quarterly earnings release, CorVel will,be ... Tuesday, August 5th at 11:30 am Eastern Time., Event: ... Dan Starck, President and CEO ... 11:30 am Eastern Time, Tuesday, August ...
... Researchers at Fred Hutchinson Cancer,Research Center have received ... Genome Research Institute to better understand the genetic,and ... is one of,four U.S. research institutes to receive ... The Hutchinson Center project, led by biostatistician and ...
... MOUNTAINSIDE, N.J., July 17 National Stem,Cell Holding, ... owned,subsidiary Proteoderm, Inc. is exhibiting at the 16th ... in Washington, DC on July,17 -- 19, 2008. ... speak as a,scientific keynote panelist. Dr. Steiner will ...
Cached Biology Technology:CorVel Corporation Announces Earnings Release Webcast 2Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases 2Hutchinson Center Receives $7.6 Million Federal Grant to Study How Genetic Variations Influence Risk of Common Diseases 3National Stem Cell Holding, Inc. (Ticker NHGI) Subsidiary Proteoderm, Inc. Debuts Cosmoceutical Line at the 2008 World Congress on Anti-Aging Medicine 2
(Date:9/15/2014)... epilepsy drug to a morphine regimen can result in ... combination can reduce the dosage of the opioid needed ... researchers at Indiana University. , The result could bring ... difficult-to-treat condition often felt in the arms and legs ... a huge unmet need for better treatments for neuropathic ...
(Date:9/15/2014)... for both plants and animals alike. , Understanding just ... lead to the design of better drugs for diabetes ... and vegetables farmers are able to grow. Stanford University ... the cell by piecing together proteins slightly wider than ... To determine the size, shape and orientation of one ...
(Date:9/15/2014)... When this week,s print issue of the journal ... up from New Mexico, Montana and even the Netherlands, ... more and more the norm in these connected times. ... it will produce innovations in biology, medicine, biotechnology and ... this scientist talked with that one, that one knew ...
Breaking Biology News(10 mins):IU study: Combining epilepsy drug, morphine can result in less pain, lower opioid doses 2X-rays unlock a protein's SWEET side 2X-rays unlock a protein's SWEET side 3Collaboration drives achievement in protein structure research 2
... Each year, millions of monarch butterflies ( Danaus ... to colonize eastern North America, but just how these ... their breeding range in spring has largely remained a ... Guelph led by Prof. Ryan Norris, Department of Integrative ...
... musculus ) happily live wherever there are humans. When ... them. New research published in BioMed Central,s open access ... techniques on modern day and ancestral mouse mitochondrial DNA ... that of Viking invasion. During the Viking age ...
... Calif., March 18, 2012 Autoimmune diseases, such as ... an immune system gone haywire, where the body,s defense ... of a protein called LYP has been implicated in ... has been unknown. Now, in a paper published March ...
Cached Biology News:Study reveals how monarch butterflies recolonize northern breeding range 2The Viking journey of mice and men 2New insight into mechanisms behind autoimmune diseases suggests a potential therapy 2
... optically clear polystyrene with frosted labeling ... for cell counting. 100% integrity tested. ... new product number, created to easily ... no availability yet, please order under ...
Packaging: package with 500 l Patent/trademark/license (electronic): (r) Registered trademark of Molecular Probes...
... VersaDoc MP 4000 System is a ... system capable of supporting a wide ... chemiluminescence, densitometry, and chemiflourescence. Red, ... imaging of multiplexed fluorescent samples, reducing ...
... hydrophobic barrier pen for immunohistochemistry and in ... frozen or paraffin-embedded tissue sections mounted on ... heat-stable, water-repellent barrier that keeps staining reagents ... of reagents when differentially staining two sections ...
Biology Products: